Released on Nov. 30, 2023, the new AFib guidance from the ACC/AHA contains update recommendations for early and aggressive rhythm control, wearables, left atrial appendage occlusion, and more.

In a new study, decreased plasma EGR1 protein levels and patients with fibromyalgia had a statistically significant relationship.

An overview of treatment regimens for HCV.

8 weeks of treatment with glecaprevir/pibrentasvir was found to be safe and effective among patients with HCV aged 3-17 years.

Experts explore the challenges of multi-product topical treatment algorithms for seborrheic dermatitis (SD) and the value of once-a-day solutions in fostering adherence, improved quality of life, and overall better outcomes.

Expert hepatologist Mark Sulkowski, MD discusses which patients are candidates for HCV treatment.

This discussion with Dr. Eichenfield featured coverage of data on ruxolitinib for eczema patients.

Expert rheumatologists discuss precision medicine in rheumatoid arthritis. In particular, they discuss available data and the value of various tools in guiding treatment selection in routine clinical practice.

Dermatologists discuss the safety and efficacy of roflumilast for seborrheic dermatitis (SD), highlighting its tolerability across backgrounds and age groups, safety in pediatric care, and the unmet need it fulfills.

Resilience of participants with fibromyalgia had a stronger protective association among participants with average null or mild pain than with moderate or severe pain.

Pretreatment vitamin D levels were associated with endoscopic improvement in patients with UC and decreased C-reactive protein levels in patients with CD.

Ophthalmology registry data show increased macular fluid volume after initial treatment are associated with increased numbers of injections in nAMD treatment.

Common themes included preferring a standard list of symptoms, active training programs, and the desire for community.

Factors associated with receiving eye care in past 12 months included a higher educational level and income, while food and housing insecurity were associated with not receiving eye care.

A trial randomizing brain-dead donor hearts to levothyroxine administration or saline has returned results challenging conventional wisdom on the topic, with data indicating thyroid hormone administration may provide no significant benefit.

Patients with juvenile onset fibromyalgia and joint hypermobility demonstrated poorer overall functioning compared with those without joint hypermobility.

A qualitative study in Denmark explores the adherence of patients with nAMD to their treatment regimen despite various barriers, including access to care and poor health literacy.

This data may bring patients with the rare immunobullous disease closer to an eventual FDA-approved treatment.

Ciprofloxacin, ceftriaxone, and piperacillin/tazobactam showed the greatest associations with adverse drug reaction case reports related to CDI.

Data from a phase 3 trial of CT-P43 in patients with moderate to severe plaque psoriasis offers additional insight into the comparative effects of the biosimilar relative to ustekinumab.

Dr Linda Stein Gold shares a clinical pearl on taking care of patents with plaque psoriasis from her practice.

Expert dermatologist shares recent data on systemic therapy for patients with moderate psoriasis.

Dr Daniel J. Clauw provides an overview of pharmacologic and nonpharmacologic therapeutic approaches for the management of fibromyalgia and comments on challenges and unmet needs for patients.

The FDA will decide on the approval of xanomeline-trospium, a dual M1/M4 muscarinic acetylcholine receptor agonist in the central nervous system, for the treatment of schizophrenia patients by September 2024.

Daniel J. Clauw, MD, describes the role the brain and CNS play in controlling the setting of nociplastic pain in patients with fibromyalgia and highlights increased patient sensitivity to sensory stimuli.